Hans Verbaan

2.7k total citations · 1 hit paper
44 papers, 2.0k citations indexed

About

Hans Verbaan is a scholar working on Hepatology, Epidemiology and Genetics. According to data from OpenAlex, Hans Verbaan has authored 44 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Hepatology, 36 papers in Epidemiology and 6 papers in Genetics. Recurrent topics in Hans Verbaan's work include Liver Disease Diagnosis and Treatment (27 papers), Hepatitis C virus research (27 papers) and Hepatitis B Virus Studies (16 papers). Hans Verbaan is often cited by papers focused on Liver Disease Diagnosis and Treatment (27 papers), Hepatitis C virus research (27 papers) and Hepatitis B Virus Studies (16 papers). Hans Verbaan collaborates with scholars based in Sweden, Denmark and Norway. Hans Verbaan's co-authors include Ingalill Friis–Liby, M. Vilien, Erik Hertervig, Per Karlén, Anders Magnuson, Per M. Hellström, Christer Grännö, Lars Blomquist, Magnus Ström and Gunnar Järnerot and has published in prestigious journals such as Gastroenterology, PLoS ONE and Hepatology.

In The Last Decade

Hans Verbaan

43 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Infliximab as Rescue Therapy in Severe to Moderately Severe Ulcerative Colitis: A Randomized, Placebo-Controlled Study

2005 789 citations Gunnar Järnerot, Erik Hertervig et al. Gastroenterology profile →

Peers

Countries citing papers authored by Hans Verbaan

Since Specialization

Citations

This map shows the geographic impact of Hans Verbaan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hans Verbaan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hans Verbaan more than expected).

Fields of papers citing papers by Hans Verbaan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hans Verbaan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hans Verbaan. The network helps show where Hans Verbaan may publish in the future.

Co-authorship network of co-authors of Hans Verbaan

This figure shows the co-authorship network connecting the top 25 collaborators of Hans Verbaan. A scholar is included among the top collaborators of Hans Verbaan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hans Verbaan. Hans Verbaan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Increased hope following successful treatment for hepatitis C infection 2017 ·Journal of Advanced Nursing ·(unknown), Olav Dalgård, Håvard Midgard, Hans Verbaan, Milada Cvancarova Småstuen, Tone Rustøen	2
2	Epidemiology and causes of death in a Swedish cohort of patients with autoimmune hepatitis 2017 ·Scandinavian Journal of Gastroenterology ·(unknown), Hanns–Ulrich Marschall, Annika Bergquist, Fredrik Rorsman, Ola Weiland, Stergios Kechagias, Nils Nyhlin, Hans Verbaan, Emma Nilsson, Mårten Werner	40
3	Peg-IFN and ribavirin treatment for recurrence of genotype 2 and 3 hepatitis C after liver transplantation 2015 ·Infectious Diseases ·(unknown), Maria Castedal, (unknown), Hans Verbaan, Henrik Gjertsen, Annika Wernerson, Ola Weiland	3
4	Genetic variants at the ITPA locus protect against ribavirin-induced hemolytic anemia and dose reduction in an HCV G2/G3 cohort 2012 ·European Journal of Gastroenterology & Hepatology ·(unknown), Espen Melum, Amir Moghaddam, Kristian Bjøro, Hans Verbaan, Helmer Ring‐Larsen, Olav Dalgård	22
5	IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection 2011 ·Research at the University of Copenhagen (University of Copenhagen) ·Amir Moghaddam, Espen Melum, Nils Reinton, (unknown), Hans Verbaan, Kristian Bjøro, Olav Dalgård	6
6	Clinical trial: colectomy after rescue therapy in ulcerative colitis – 3‐year follow‐up of the Swedish‐Danish controlled infliximab study 2010 ·Alimentary Pharmacology & Therapeutics ·(unknown), G Järnerot, Erik Hertervig, Ingalill Friis–Liby, L. Blomquist, Per Karlén, Christer Grännö, M. Vilien, Morten B. Strøm, Hans Verbaan, Per M. Hellström, Anders Magnuson, Jonas Halfvarson, Curt Tysk	133
7	Il28B Genetic Variation And Treatment Response In Patients With Hcv Genotype 3 Infection 2010 ·Hepatology ·Olav Dalgård, Amir Moghaddam, Hans Verbaan, Helmer Ring‐Larsen, Kristian Bjøro, Espen Melum	4
8	In patients with HCV genotype 2 or 3 infection and RVR 14 weeks treatment is noninferior to 24 weeks. Pooled analysis of two Scandinavian trials 2010 ·European Journal of Gastroenterology & Hepatology ·Olav Dalgård, Kristian Bjøro, Helmer Ring‐Larsen, Hans Verbaan	7
9	Health-related quality of life in patients with different stages of liver disease induced by hepatitis C 2009 ·Scandinavian Journal of Gastroenterology ·Einar Björnsson, Hans Verbaan, Antti Oksanen, Aril Frydén, Jonas Johansson, (unknown), Olav Dalgård, Evangelos Kalaitzakis	52
10	Characterisation and utility of thiopurine methyltransferase and thiopurine metabolite measurements in autoimmune hepatitis 2009 ·Journal of Hepatology ·Ulf Hindorf, (unknown), Annika Bergquist, Hans Verbaan, Hanne Prytz, Sven Wallerstedt, Mårten Werner, Rolf Olsson, Einar Björnsson, Curt Peterson, Sven Almér	41
11	IN PATIENTS WITH HCV GENOTYPE 2 OR 3 INFECTION AND RVR 14 WEEKS TREATMENT IS NON-INFERIOR TO 24 WEEKS. POOLED ANALYSIS OF TWO SCANDINAVIAN TRIALS 2008 ·Hepatology ·Olav Dalgård, Hans Verbaan, Helmer Ring‐Larsen, Kristian Bjøro	2
12	Colectomy after rescue therapy for intravenous-steroid resistant acute ulcerative colitis : a 3-year follow-up study of the Swedish-Danish infliximab/placebo trial 2008 ·Gut ·Anders Gustavsson, Gunnar Järnerot, Erik Hertervig, Ingalill Friis–Liby, L. Blomquist, Per Karlén, Christer Grännö, M. Vilien, (unknown), Hans Verbaan, Per M. Hellström, Jonas Halfvarson, Anders Magnuson, Curt Tysk	4
13	High levels of serum antibodies to cell surface proteins ofHelicobacter pullorumandHelicobacter pyloriin hepatitis C virus-infected patients 2008 ·Scandinavian Journal of Gastroenterology ·(unknown), Ingrid Nilsson, Hans Verbaan, Torkel Wadström, Åsa Ljungh	4
14	Prevalence of hepatitis C in Swedish diabetics is low and comparable to that in health care workers 2008 ·European Journal of Gastroenterology & Hepatology ·Klas Sjöberg, Anders Widell, Hans Verbaan	6
15	A 2-year follow-up of the swedish-danish Infliximab/Placebo trial in steroid resistant acute ulcerative colitis 2007 ·Gastroenterology ·Anders Gustavsson, (unknown), Erik Hertervig, (unknown), Lars Blomquist, Per Karlén, Christer Grännö, M. Vilien, Magnus Ström, (unknown), Hans Verbaan, Per M. Hellström, Jonas Halfvarson, Anders Magnuson, Curt Tysk	14
16	Capsule endoscopic diagnosis of small bowel Crohn's disease: a prospective, comparative study of capsule enteroscopy, barium enterography, push enteroscopy and ileo-colonoscopy 2006 ·Scandinavian Journal of Gastroenterology ·Ervin Tóth, Per Almqvist, Cecilia Benoni, Olle Ekberg, Frans‐Thomas Fork, O Grip, T. Gustafson, Stefan Lindgren, Bodil Ohlsson, Rolf Olsson, Klas Sjöberg, Hans Verbaan, Henrik Thorlacius	4
17	Clinical spectrum of hepatitis C‐related liver disease and response to treatment with interferon and ribavirin in haemophilia or von Willebrand disease 2001 ·British Journal of Haematology ·Stefan Lethagen, Anders Widell, Erik Berntorp, Hans Verbaan, Stefan Lindgren	23
18	Anti‐neutrophil cytoplasmic antibodies in patients with chronic liver diseases: Prevalence, antigen specificity and predictive value for diagnosis of autoimmune liver disease 2000 ·Journal of Gastroenterology and Hepatology ·Stefan Lindgren, (unknown), Lennart Nässberger, Hans Verbaan, Jörgen Wieslander, (unknown)	30
19	Alcohol Abuse Exaggerates Autonomic Dysfunction in Chronic Liver Disease 1996 ·Scandinavian Journal of Gastroenterology ·Stefan Lindgren, B. Lilja, Hans Verbaan, G. Sundkvist	14
20	Intravenous Drug Abuse–the Major Route of Hepatitis C Virus Transmission among Alcohol-Dependent Individuals? 1993 ·Scandinavian Journal of Gastroenterology ·Hans Verbaan, Karl‐Erik Andersson, Sten Eriksson	46

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact